Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Evotec and Aspireo Enter into Strategic Advisory Agreement

Published: Wednesday, October 03, 2012
Last Updated: Wednesday, October 03, 2012
Bookmark and Share
Teaming up to partner Aspireo’s Somatoprim (DG3173).

Evotec AG and Aspireo Pharmaceuticals Limited have announced that they have entered into a strategic advisory agreement for support in the development and partnering of Aspireo’s Somatoprim.

Somatoprim (DG3173) is a new molecular entity somatostatin analogue with a unique, potentially best-in-class, pharmacological profile currently in phase I of clinical development.

Somatostatin analogues have been approved for the treatment of Acromegaly, carcinoid tumours, and Cushing’s disease but also have demonstrated significant potential in Diabetic Retinopathy.

Somatostatin analogues are generating more than USD 1.5 billion in annual sales in a continually growing market.

Under the terms of the agreement, Evotec will provide Aspireo with strategic and operational advice on the partnering of Somatoprim. In addition, Evotec will consult Aspireo on matters of clinical and pre-clinical development.

In return for such services, Evotec will retain advisory fees as well as participate in the economic success of Somatoprim.

Dr Werner Lanthaler, CEO of Evotec, commented: “This agreement marks a new business model for asset centric biotech companies who want to combine capital efficiency with access to high quality and often very specialized pre-clinical, clinical, regulatory and commercial expertise. Aspireo is a pioneer in pursuing a model of extreme capital efficiency while not compromising on quality and speed. We are excited to advise and support Aspireo in its partnering efforts for Somatoprim.”

Carsten Dehning, CEO of Aspireo, added: “Aspireo is combining the strengths of a project focused company with the benefits of accessing complete teams with leading expertise drug development and proven partnering skills. This strategic advisory agreement comes at a time when we are getting closer to reaching clinical proof of concept for Somatoprim. Evotec’s reach into the pharmaceutical industry, combined with its own experience in clinical development and partnering of clinical stage assets, makes it the partner of choice for Aspireo.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Evotec Awarded Contract to Manage NCI CBC Screening Libraries Center
Company will provide compound management services for a period of five years.
Friday, October 09, 2015
Evotec Enters into Agreement with Pfizer
Licence and collaboration agreement in the field of tissue fibrosis.
Friday, September 11, 2015
Evotec and Sanofi Enter into Exclusive Negotiations
Goal to improve innovation effectiveness in drug discovery and pre-clinical development.
Thursday, December 04, 2014
Evotec Receives Milestone Payment as part of its Discovery Alliance with Boehringer Ingelheim
Company receives milestone payment of € 1.0 m.
Thursday, June 19, 2014
Evotec to Establish an Anti-infectives Platform with the Acquisition of Euprotec Ltd
Adds key know-how and infectious disease therapeutic area capabilities.
Thursday, May 29, 2014
Evotec Acquires UK-Based CRO Euprotec
Company announce the acquisition of all shares in Euprotec Ltd, a recognised leader in anti-infective drug discovery services
Thursday, May 29, 2014
Evotec Acquires Bionamics to Accelerate 'EVT Innovate' Strategy
Expanding discovery pipeline with portfolio of projects especially in Multiple Sclerosis and CNS.
Saturday, March 29, 2014
Evotec Receives Pre-Clinical Milestone with Boehringer Ingelheim
The milestone relates to the transition of an oncology molecule into pre-clinical development.
Tuesday, December 10, 2013
Evotec Achieves First Milestones in Multi-target Deal with UCB
Projects move into hit-to-lead and lead optimization.
Thursday, October 31, 2013
Evotec raises € 30 m from Biotechnology Value Fund
Biotechnology Value Fund, L.P. and other affiliates of US investment firm BVF partners L.P. (“BVF”) invest € 30 M in new Evotec shares.
Monday, September 02, 2013
Evotec Expands Collaboration with MedImmune
Evotec AG has expanded the scope of its collaboration with MedImmune after hitting a key milestone. Evotec achieved a milestone payment of €0.5 m.
Monday, January 07, 2013
Evotec Enters Biology Collaboration with Probiodrug
Evotec will setup and validate assays to support the pre-clinical and clinical development of QC inhibitors in Alzheimer’s disease.
Thursday, November 29, 2012
Evotec Extends Ongoing Collaboration with CHDI Foundation
Collaboration aims to accelerate development of drugs that slow the progression of Huntington's disease.
Monday, November 05, 2012
Evotec and Bayer Enter into Multi-target Alliance to Fight Endometriosis
Companies have entered into a five-year, multi-target collaboration with the goal of developing three clinical candidates for the treatment of endometriosis.
Monday, October 01, 2012
Evotec Receives Milestone Payment as Part of its Discovery Alliance with Boehringer Ingelheim
Company receives milestone payment of EUR 2.5 million.
Thursday, September 27, 2012
Scientific News
Therapy Halts Progression of Lou Gehrig’s Disease
Researchers at Oregon State University announced today that they have essentially stopped the progression of amyotrophic lateral sclerosis (ALS), or Lou Gehrig’s disease, for nearly two years in one type of mouse model used to study the disease – allowing the mice to approach their normal lifespan.
New Mechanism of Antitumor Action Identified
A team of UAB researchers and collaborators from the Catalan biotech company Ability Pharmaceuticals (UAB Research Park), have described a new mechanism of anti-tumour action, identified during the study and development of the new drug ABTL0812.
Experimental Combination Surprises with Anti-HIV Effectiveness
A compound developed to protect the nervous system from HIV surprised researchers by augmenting the effectiveness of an investigational antiretroviral drug beyond anything expected.
UTSW Researchers Identifies How Drugs Alter Pancreatic Cancer Cells
The findings were published in Cell Reports.
Researchers Identify Process that Causes Chronic Neonatal Lung Disease
Study determines how the NLRP3 inflammasome activates the protein Interleukin 1 beta.
Dengue Vaccine Enters Phase 3 Trial
Investigational vaccine to prevent ‘breakbone fever’ developed at NIH.
Trying to Conceive Soon After a Pregnancy Loss May Increase Chances of Live Birth
NIH study finds no reason for delaying pregnancy attempts after a loss without complications.
BRCA1 Deficiency Increases the Sensitivity of Ovarian Cancer Cells to Auranofin
An anti-rheumatic drug could improve the prognosis for ovarian cancer patients exhibiting a deficiency of the DNA repair protein BRCA1, a study suggests.
Shingles Vaccine Helps Protect Older Patients with End-stage Renal Disease
Kaiser Permanente study advances knowledge about safety and effectiveness of vaccine commonly given to older adults.
AMRI Acquires Whitehouse Laboratories
Strategically extends AMRI's analytical offerings in rapidly expanding area of outsourcing services.
Scroll Up
Scroll Down
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!